WORKPACKAGES
WP1
Characterization and modelling of human plaque Mo/MP subsets
Objective: To define and characterize blood-born and resident culprit (and protective) monocyte/macrophage (Mo/MP) subsets in human rupture-prone plaques and their mouse counterparts using advanced 16-color multispectral imaging and functionomics profiling.
WP2
Selection of plaque and Mo/MP-specific scFvphages
Objective: To identify human antibody fragments that specifically target plaque-homing and monocyte/macrophage (Mo/MP) subsets using a combination of computational (in silico) methods and biological approaches.
WP3
Optimization of HuAb formats for imaging and therap
Objective: To engineer and optimize human antibody formats from selected single-chain variable fragments (scFvs) for imaging applications and to develop bispecific antibodies (bsAbs) for therapeutic use.
WP4
Final plaque-targeted scFv-Fc HuAb leads’selection /identification of their targets
Objective: To validate imaging and therapeutic candidates derived from scFv-Fc in high-risk plaques, and to predict their molecular targets using computational methods (in silico), followed by experimental validation.
WP5
Theranostic development of HuAbs
Objective: To develop human antibody (HuAb) candidates into imaging and diagnostic agents, as well as therapeutic solutions for atherosclerosis.
WP6
Communication, dissemination and exploitation
Objective: To make project results visible and maximize the project’s overall impact.
WP7
Project management and coordination
Objective: To ensure the overall management of the project, facilitating coordination and communication among partners in line with the agreed commitments and schedule for delivering technical and financial reports.